title: Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
abstract: Vancomycin, linezolid, and daptomycin are very active against staphylococci, but isolates with decreased susceptibility to these antimicrobial agents are isolated sporadically. A total of 19,350 Staphylococcus aureus isolates (51% methicillin resistant [MRSA]) and 3,270 coagulase-negative staphylococci (CoNS) were collected consecutively from 82 U.S. medical centers from January 2008 to December 2011 and tested for susceptibility against ceftaroline and comparator agents by the reference broth microdilution method. Among S. aureus strains, 14 isolates (0.07%) exhibited decreased susceptibility to linezolid (MIC, ≥ 8 μg/ml), 18 (0.09%) to daptomycin (MIC, ≥ 2 μg/ml), and 369 (1.9%) to vancomycin (MIC, ≥ 2 μg/ml; 368 isolates at 2 μg/ml and 1 at 4 μg/ml). Fifty-one (1.6%) CoNS were linezolid resistant (MIC, ≥ 8 μg/ml), and four (0.12%) were daptomycin nonsusceptible (MIC, ≥ 2 μg/ml). Ceftaroline was very active against S. aureus overall (MIC50/90, 0.5/1 μg/ml; 98.5% susceptible), including MRSA (MIC50/90, 0.5/1 μg/ml; 97.2% susceptible). All daptomycin-nonsusceptible and 85.7% of linezolid-resistant S. aureus isolates were susceptible to ceftaroline. Against S. aureus isolates with a vancomycin MIC of ≥ 2 μg/ml, 91.9, 96.2, and 98.9% were susceptible to ceftaroline, daptomycin, and linezolid, respectively. CoNS strains were susceptible to ceftaroline (MIC50/90, 0.25/0.5 μg/ml; 99.1% inhibited at ≤ 1 μg/ml), including methicillin-resistant (MIC50/90, 0.25/0.5 μg/ml), linezolid-resistant (MIC50/90, 0.5/0.5 μg/ml), and daptomycin-nonsusceptible (4 isolates; MIC range, 0.03 to 0.12 μg/ml) strains. In conclusion, ceftaroline demonstrated potent in vitro activity against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin, and it may represent a valuable treatment option for infections caused by these multidrug-resistant staphylococci.
authors: JMI Laboratories, North Liberty, Iowa, USA. helio-sader@jmilabs.com
authors: Helio S
authors: HS
authors: Sader
authors: Robert K
authors: RK
authors: Flamm
authors: Ronald N
authors: RN
authors: Jones
mesh_terms: D000081:Acetamides / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology*; D017576:Daptomycin / Q000494:pharmacology; D006761:Hospitals; D006801:Humans; D000069349:Linezolid; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D023303:Oxazolidinones / Q000494:pharmacology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000276:immunology; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D014640:Vancomycin / Q000494:pharmacology; D000097583:Ceftaroline
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D017576:Daptomycin; D000069349:Linezolid; D023303:Oxazolidinones; D014640:Vancomycin; D000097583:Ceftaroline
references: Int J Antimicrob Agents. 2011 Jun;37(6):584-5
references: 21497060
references: Emerg Infect Dis. 2009 Sep;15(9):1516-8
references: 19788830
references: Pharmacotherapy. 2011 Sep;31(9):912-21
references: 21923592
references: Int J Antimicrob Agents. 2011 Mar;37(3):248-52
references: 21295951
references: Diagn Microbiol Infect Dis. 2011 Jul;70(3):412-6
references: 21546202
references: Ann Intern Med. 2008 Feb 19;148(4):249-57
references: 18283202
references: Clin Infect Dis. 2010 Sep 15;51 Suppl 2:S183-97
references: 20731576
references: Clin Microbiol Infect. 2009 Feb;15(2):125-36
references: 19291144
references: Medicine (Baltimore). 2011 Nov;90(6):390-395
references: 22033455
references: Clin Infect Dis. 2012 Sep;55 Suppl 3:S173-80
references: 22903949
references: Antimicrob Agents Chemother. 2012 Dec;56(12):6192-200
references: 22985884
references: Antimicrob Agents Chemother. 2012 Oct;56(10):5296-302
references: 22869564
references: Clin Infect Dis. 2011 Jan 1;52(1):99-114
references: 21148528
references: Clin Infect Dis. 2012 Mar;54(6):755-71
references: 22302374
references: Antimicrob Agents Chemother. 2012 Jun;56(6):2933-40
references: 22470115
references: J Clin Microbiol. 2012 Aug;50(8):2548-52
references: 22593595
references: Antimicrob Agents Chemother. 2011 Apr;55(4):1598-605
references: 21220533